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Objective. Insulin resistance (IR) and ovarian and adrenal hyperandrogenism are a common finding in women with polycystic
ovary syndrome (PCOS). The aim of the present study was to access possible differences in insulin resistance, gonadotropins, and
androgens production in obese and nonobese PCOS women. Study Design. We studied 37 PCOS women (16 nonobese and 21
obese) and 18 nonobese controls. Fasting glucose, insulin, androgens, and gonadotropins levels were determined. Salivary cortisol
wasmeasured basal and in themorning after dexamethasone (DEX) 0.25mg. Results.Nonobese PCOSwomen showed higher basal
salivary cortisol and serum dehydroepiandrosterone sulfate and luteinizing hormone (LH) levels than controls and obese PCOS.
These hormones levels did not differ between the obese and control groups. After DEX administration no differences were found
between the three groups. In PCOS women, salivary cortisol levels showed negative correlation with BMI (𝑟 = −0.52; 𝑃 = 0.001)
and insulin (𝑟 = −0.47; 𝑃 = 0.003) and positive correlation with LH (𝑟 = 0.40; 𝑃 = 0.016). Conclusion. Our results show an
increased adrenocortical production in nonobese PCOS women, not related to IR and associated with a normal hypothalamic-
pituitary-adrenal suppression. Higher LH levels might be involved in this event.
1. Introduction
Ovarian hyperandrogenism is a hallmark of polycystic ovary
syndrome (PCOS) and insulin resistance (IR) is a common
finding in these women [1–3]. IR is present in 50 to 70% of
PCOSwomen and plays a significant role in the physiopathol-
ogy of this syndrome.The resultant increases in insulin levels
stimulate ovarian androgen production, acting directly on
ovarian theca cells, and also reduces sex hormone-binding
globulin (SHBG) which increases free androgens levels [1–3].
Furthermore, hyperinsulinism decreases hepatic production
of insulin-like growth factor-binding proteins (IGFBPs),
leading to increase in insulin-like growth factor 1 (IGF-
1) bioavailability which also stimulates ovarian androgen
production [1–3]. Insulin also can bind IGF-1 receptor and
activate the intracellular events contributing to the ovarian
steroidogenic abnormalities found in PCOS women [1–3].
Functional adrenal hyperandrogenism is found in
approximately half of PCOS women [1]. These women
demonstrate a generalized hypersecretion of adrenocortical
products, both in a basal condition and in response to
adrenocorticotropic hormone (ACTH) stimulation [4–8],
although the mechanisms of these abnormalities are still
unclear. Similarly unclear are the effects of insulin resistance
on adrenal function in PCOS women [1–9].
Although the prevalence of insulin resistance in women
with PCOS is higher compared to healthy women with sim-
ilar body mass index (BMI), there is a distinguished number
of PCOS women, mainly the less obese, that do not show
insulin resistance [3]. Presumably a different physiopathology
is present in these women.
The aim of the present study was to access possible
differences in insulin resistance, gonadotropins, and andro-
gens production in obese and nonobese PCOS women and
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the influence of insulin resistance on the hormonal profile
of these two groups of women. A low-dose (DEX) (0.25mg)
suppression test with measurements of salivary cortisol,
which closely correlates with the concentration of serum
free cortisol [10], was used to evaluate the hypothalamic-
pituitary-adrenal (HPA) axis.This test induces amoremodest
ACTH suppression than the standard DEX (1.0mg) test,
enabling the detection of subtle differences in HPA axis
feedback sensitivity to glucocorticoids [11].
2. Materials and Methods
2.1. Population. Our study included 37 PCOS women who
were divided in 2 groups: 16 nonobese (BMI <30Kg/m2) and
21 obese (BMI ≥30Kg/m2) and 18 nonobese healthy women
with age between 16 and 45 years. Subjects were recruited
from the Endocrinology Division of Federal University of
Sa˜o Paulo (UNIFESP), Brazil. The diagnosis of PCOS was
based on the latest 2003 Rotterdam consensus [12] requiring
the presence of at least two of the following features: (1)
oligomenorrhea or chronic anovulation, (2) clinical and/or
biochemical hyperandrogenism, and (3) ultrasound (US)
appearance of polycystic ovaries, after the exclusion of other
known causes of hyperandrogenemia such as congenital
adrenal hyperplasia, androgen-secreting tumors, and Cush-
ing’s syndrome. Exclusion criteria included the use of oral
contraceptives, corticosteroids, and antidiabetic drugs in the
last 3 months. We also excluded patients with diabetes mel-
litus, untreated hypothyroidism, and renal, hepatic, cardiac,
or pulmonary disease. The study was approved by the Ethics
Committee of UNIFESP, and an informed written consent
was obtained from all subjects.
2.2. Clinical, Anthropometrical, and Biochemical Parameters.
A questionnaire was used to document personal, medical,
and drug history, regularity and length of menstrual cycles,
and ovulation status. Signs of androgen excess (hirsutism,
alopecia, and acne) were noted in the physical examination.
Hirsutism with a Ferriman-Gallwey score of 8 or above was
considered as clinical evidence of androgen excess. Body
weight (in kilograms), body height (in meters), and waist
and hip circumference (in centimeters) weremeasured.Waist
circumference was taken as the narrowest measurement
midway between the top of the iliac crest and the lower
rib margin, whereas the hip circumference was taken as the
widest measurement at the level of the greater trochanters.
BMI was calculated from the ratio between weight and height
squared.
Blood specimens were obtained after a 12-hour overnight
fast from all subjects in the early follicular phase of the
menstrual cycle or after a period of amenorrhea above 3
months for measurement of plasma glucose, luteinizing hor-
mone (LH), follicle-stimulating hormone (FSH), androgenic
profile, and serum insulin. A standard 75-gram oral glucose
tolerance test (OGTT) was performed in PCOS patients for
insulin sensitive index (ISI) calculation.
The assessment of HPA axis included low-dose (0.25mg)
DEX suppression test with measurement of salivary cortisol.
The women received two Salivettes (Sarstedt, Rommelsdorf,
Germany) which consist of a small cotton swab inside a
centrifugation tube used to collect saliva and a half tablet of
0.5mg of dexamethasone (Decadron, Ache´, Brazil). Salivary
sample was obtained between 7:00 and 8:00 am in the day of
the administration of DEX, which was taken between 11:00
and 12:00 pm. Another salivary sample was obtained on the
next morning between 7:00 and 8:00 am. To analyze the
results we used an index of percentage of salivary suppression
(% cortisol suppression) calculated as the difference between
the post-DEX cortisol level and baseline cortisol levels
divided by baseline cortisol levels and multiplied by 100.
2.3. LaboratoryAnalysis. Plasma glucosewasmeasured using
ADVIA 2400 Chemistry System (Siemens, Tarrytown, NY).
Dehydroepiandrosterone (DHEA) and 17OH-progesterone
levels were measured by enzyme-linked immunosorbent
assays (Diagnostic Biochem Canada, Ontario, Canada and
Labor Diagnostika Nod GmbH, Nortdhorn, Germany, resp.).
Total testosterone (TT), dehydroepiandrosterone sulfate
(DHEA-S), LH, FSH, and insulin were measured using Uni-
Cel Dxl 800 Immunoassay System (Beckman Coulter, Brea,
CA). The within-assay coefficient of variation of testosterone
was 1.99%, and the between-assay coefficient was 4.22%.
There are some limitations to measuring testosterone using
a chemiluminescence immunoassay, but this was the only
laboratory technique available. Androstenedione and sex
hormone-binding globulin (SHBG) were measured using
IMMULITE 2000 Immunoassay System (Siemens). Serum-
free testosterone (FT) and bioavailable testosterone were esti-
mated by the formula as previously validated by Vermeulen
et al. [13] (available at http://www.issam.ch/freetesto.htm).
Free androgen index (FAI) was calculated according to the
formula 100 × [TT (nmol/L)/SHBG]. IR was estimated
using the homeostasis model assessment for insulin resis-
tance (HOMA-IR) by dividing the product of fasting insulin
(microinternational units (𝜇IU)/mL) and glucose (mmol/L)
by 22.5. ISI was calculated according to the formula devel-
oped by Belfiore et al. [14]: 2/((INSp × GLYp) + 1), where
INSp and GLYp are obtained by dividing the sum of plasma
insulin (𝜇IU/mL) and glycemia (mmol/L) (measured at 0
and 2 hours after oral glucose load) by the sum of the
respective values of the normal population. Normal reference
values were obtained in 35 normotensive individuals with
normal BMI. All biochemical assays were performed at the
Sleep Institute Laboratory. Salivary cortisol was measured
by radioimmunoassay in a single assay run in the Steroid
Laboratory of the Endocrinology Division of UNIFESP. The
lowest level of detection of salivary cortisol was 5 ng/dL and
the between-assay coefficient of variation was 13.1%.
2.4. Statistical Analysis. Data are expressed as mean (SD).
Comparison of mean values between controls, nonobese,
and obese PCOS women was performed using ANOVA.
Correlation between variables was determined using linear
correlation test. The Fisher test was used to analyze the
association between the presence of amenorrhea in the two
groups of PCOS. Linear regression analysis was used to
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Figure 1: Correlation between basal salivary cortisol and luteinizing
hormone (LH) levels in the two groups of women with polycystic
ovary syndrome.
identify the hormones associated with cortisol levels among
PCOS subjects. A 𝑃 value < 0.05 was considered significant.
Statistical analyses were performed with the Statistical Pack-
age for Social Sciences for Windows, version 19.0 (SPSS Inc,
Chicago, IL).
3. Results
The anthropometrical and biochemical characteristics of all
subjects are summarized in Table 1. The proportions of
patients with amenorrhea were not different between the two
PCOS groups of patients (25% in nonobese and 33% in obese;
𝑃 = 0.580). Obese PCOS women had higher BMI and waist-
to-hip ratio than nonobese PCOS subjects and controls, but
no differences were found between controls and nonobese
PCOS women.
Nonobese PCOS women had higher LH, DHEA-S, and
basal salivary cortisol (Figure 1) than control and obese PCOS
women.These hormones levels were similar between control
and obese PCOS women. Although there was a trend for a
difference inDHEA levels between the twoPCOS groups, this
difference did not reach statistical significance (𝑃 = 0.072).
With regard to androgens profile, total and free testos-
terones and FAI were similar between PCOS groups and
higher than control group although bioavailable testosterone
showed to be higher only when obese PCOS group was
compared to control with no difference between the two
groups of PCOS. Androstenedione was higher in nonobese
PCOS women when compared to controls with no difference
between the two groups of PCOS.
There were no differences in fasting glucose levels among
the three groups although HOMA-IR and fasting insulin lev-
els were higher in obese PCOS group compared to nonobese
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Figure 2: Correlation between basal salivary cortisol levels and
body mass index (BMI) in women with polycystic ovary syndrome.
PCOS and control. There were no statistical differences in
salivary cortisol levels after DEX suppression test among the
three groups.
In the total group of PCOS, salivary cortisol levels showed
positive and significant correlation with LH levels (𝑟 = 0.40;
𝑃 = 0.016) (Figure 1) and negative correlation with HOMA-
IR (𝑟 = −0.48; 𝑃 = 0.003), fasting insulin levels (𝑟 = −0.47;
𝑃 = 0.003), and BMI (𝑟 = −0.52; 𝑃 = 0.001) (Figure 2).There
was a marginally significant positive correlation between
basal salivary cortisol and DHEA levels (𝑟 = 0.31; 𝑃 = 0.061)
and DHEA-S (𝑟 = 0.31; 𝑃 = 0.063) levels. LH levels also
showed negative and significant correlation with BMI (𝑟 =
−0.36; 𝑃 = 0.030).
In linear regression analysis among PCOS subjects, with
LH and fasting insulin as independent variables and salivary
cortisol as dependent variable, both hormones showed to
have significant and independent association with cortisol
levels: LH showed positive association and insulin negative
association (Table 2).
4. Discussion
In the present study we showed that there is no hyperactivity
of HPA axis in PCOS women as the suppression of salivary
cortisol after a low dose of DEX was similar in these women
and in controls.The presence of obesity also did not interfere
in low-dose DEX suppression.
Studies about cortisol production and metabolism in
PCOS subjects demonstrate heterogeneous results. Some of
them show normal basal cortisol levels [15–19], while others
show higher cortisol plasma levels [5–7, 20], higher ACTH
levels [5, 7], and hyperresponsiveness of adrenal to ACTH
[4, 7, 8, 17]. A possible explanation for this heterogeneity is
the wide range of BMI included in these analyzes. We found
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Table 1: Clinical and biochemical characteristics of all subjects.
Control PCOS non obese PCOS obese
𝑛 18 16 21
Presence of amenorrhea 0% 25%∗ 33%#
Age (years) 32.7 ± 6.2 26.1 ± 5.5∗ 30.4 ± 6.9
BMI (Kg/m2) 23.9 ± 3.6 25.2 ± 3.3 37.9 ± 4.7#§
Waist (cm) 81.6 ± 8.0 86.1 ± 11.0 114.4 ± 13.8#§
Waist-hip ratio 0.9 ± 0.1 0.9 ± 0.1 0.98 ± 0.1#§
LH (mIU/mL) 5.6 ± 2.0 13.7 ± 11.3∗ 6.9 ± 3.6§
FSH (mIU/mL) 7.2 ± 1.4 6.1 ± 1.3 5.2 ± 1.2#
Androstenedione (ng/mL) 1.7 ± 0.8 3.3 ± 1.9∗ 2.8 ± 2.1
DHEA (ng/mL) 5.5 ± 3.4 13.8 ± 10.8∗ 7.8 ± 8.3
DHEA-S (𝜇g/dL) 119.4 ± 61.7 192.9 ± 67.9∗ 136.6 ± 66.3§
Total testosterone (ng/dL) 33.8 ± 12.4 64.8 ± 29.6∗ 62.0 ± 40.6#
SHBG (nmol/L) 59.1 ± 24.8 37.1 ± 20.7∗ 26.7 ± 13.4#
FAI 2.4 ± 1.2 8.5 ± 8.8∗ 10.0 ± 9.0#
Free testosterone (ng/dL) 0.5 ± 0.2 1.3 ± 0.9∗ 1.4 ± 1.1#
Bioavailable testosterone (ng/dL) 11.0 ± 4.3 23.0 ± 11.2 32.0 ± 24.8#
Fasting glucose (mg/dL) 90.6 ± 9.4 91.9 ± 11.3 92.7 ± 8.9
Fasting insulin (𝜇U/mL) 6.6 ± 2.7 8.4 ± 5.7 13.5 ± 5.6#§
HOMA-IR (𝜇IU/mL) 1.5 ± 0.6 2.0 ± 1.5 3.1 ± 1.4#§
Basal cortisol (ng/dL) 1016.6 ± 367.0 1473.0 ± 539.1∗ 1011.4 ± 512.8§
Cortisol after DEX (ng/dL) 198.9 ± 219.7 282.7 ± 329.1 162.7 ± 176.4
󳵻 cortisol (ng/dL) 817.7 ± 406.7 1190.0 ± 549.7 848.8 ± 489.6
Cortisol supression (%) −78.7 ± 25.3 −80.8 ± 20.7 −82.5 ± 16.5
∗
𝑃 < .05 PCOS non obese versus control.
#
𝑃 < .05 PCOS obese versus control.
§
𝑃 < .05 PCOS obese versus PCOS non obese.
Table 2: Linear regression analysis of the hormomes that influence
in cortisol levels among PCOS subjects.
Beta 95% Confidence Interval 𝑃
LH 0.34 3.8–42.0 .020
Fasting insulin −0.43 −65.9–−13.0 .005
higher levels of basal salivary cortisol in nonobese PCOS
women compared with obese PCOS and nonobese controls.
Our results are partly in accordancewith a recent studywhere
lean PCOS had higher basal cortisol levels compared to obese
PCOS and lean controls, although LH levels did not show
similar pattern [21].
Basal levels of DHEA-S also showed similar pattern for
basal levels of salivary cortisol with higher values in nonobese
PCOS women compared to obese PCOS and nonobese
controls. The other androgens levels were similar in both
PCOS groups, and, as expected, they were higher in PCOS
women than in controls. DHEA-S is primarily secreted by
the adrenals as there is maintenance of its levels in women
with premature ovarian failure [22, 23] and absence of this
hormone in the ovarian vein after catheterization [20]. These
results suggest that adrenals cortex has an important role in
androgen production only in nonobese PCOS women.
Another substantial difference between PCOS groups in
our study was related to LH levels. Gonadotropin-secretory
changes, with a characteristic increase in LH relative to FSH
release, have long been appreciated in PCOS. The increase
in LH pulse frequency reflects an increase in GnRH release
and suggests the presence of a hypothalamic defect in this
group of women [1]. We found that nonobese PCOS women
had higher levels of LH compared to the other two groups,
and the level of this hormone was similar in controls and
obese PCOS women. We also found a negative correlation
between LH levels and BMI in PCOS women. Based on these
results and in previous studies [22, 24–26], we can assume
that there are two distinct groups of PCOS: one composed of
nonobese, noninsulin resistant women, showing higher levels
of LH and adrenocortical hormones (cortisol and DHEA-
S) and another composed of obese, insulin resistant women
showing lower levels of LH and adrenocortical products. Our
control group was composed only of nonobese women, who
showed levels of cortisol and LH comparable to those of obese
PCOS women.
We found a significant and positive correlation between
salivary cortisol and LH levels in PCOS women. This corre-
lation was previously found in postmenopausal women who
also present high levels of LH [27, 28]. Several studies have
demonstrated the presence of LH receptors in adrenocor-
tical cells which also bind human chorionic gonadotropin
(hCG) and their potential to induce local steroidogenesis
[29–36]. In situ hybridization and immunocytochemistry
also demonstrated that the adrenal zona reticularis and the
deeper layer of adrenal zona fasciculada contain LH/hCG
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receptors [31]. In addition, it has been demonstrated that
administration of hCG stimulates cortisol production in
guinea-pig adrenal cells [30], increases DHEA-S production
in human fetal adrenal gland [29], and stimulates DHEA-
S production in human adrenocortical carcinoma cells [35].
Study including 2 womenwith Cushing’s syndrome and bilat-
eral adrenal hyperplasia demonstrated pronounced cortisol
rise after GnRH administration and, in vitro, the adrenal cells
of these women also responded to hCG exposure increasing
cortisol production. Furthermore, LH receptor mRNA was
demonstrated in adrenal tissue of both patients [34]. Lacroix
et al. [32] reported awomanwith bilateral adrenal hyperplasia
who presented high cortisol levels and Cushing’s syndrome
during her pregnancies andpermanent hypercortisolismonly
after menopause. This patient showed increased cortisol
secretion in response to LH and hCG administration. In
addition, long-term suppression of LH by leuprolide acetate
administration resulted in complete reversal of Cushing’s
syndrome. It raises the possibility of an overexpression of
LH receptors in adrenal gland also in nonobese women with
PCOS.
Supporting the idea that high LH levels are responsible for
the adrenocortical hyperactivity in nonobese PCOS women,
Kero et al. [33] showed the development of polycystic ovaries
and bilateral adrenal hyperplasia, with increased androgen
and cortisol production, in a transgenic mouse model with
a high constitutive LH production. Mazzuco et al. [36]
demonstrated in amousemodel transplantedwith genetically
modified bovine adrenocortical cells with an overexpression
of LH/hCG receptor gene that it was able to provoke subclin-
ical or mild hypercortisolism.
The finding in our study that nonobese PCOS patients
have increased adrenocortical production with normal sup-
pressible cortisol production after low dose of DEX, and
a demonstration of a possible influence of LH in adrenal
steroidogenesis as described before suggests that LH might
influence adrenocortical production in nonobese PCOS
women, presumably increasing the adrenocortical response
to ACTH. This hypothesis was proposed in 1999 by Lacroix
et al. [32] who showed increases in cortisol levels after LH
administration, which were proportional to ACTH levels in
two healthy women in whom the secretion of endogenous
LH had been previously suppressed.The same group demon-
strated that the suppression of ACTH by pretreatment with
DEX prevented the increase of cortisol after LH injection.
Our group of obese PCOSwasmore insulin resistant than
the nonobese group and, as we have already described, they
had lower levels of adrenocortical products (DHEA-S and
cortisol).The effect of insulin on adrenal activity is controver-
sial. Some studies suggest that insulin is a negativemodulator
of adrenal androgen metabolism [37, 38], although some
studies using insulin sensitizers in PCOS women showed
a decrease of adrenal androgens after their administration
[9, 39]; however this event could be consequent to decreases
in LH levels that also occurs after metformin administration
to these women [39]. We found a significant and negative
correlation between basal cortisol and HOMA-IR and fasting
insulin levels in PCOS women and a positive correlation
between basal cortisol and ISI. Our results are in accordance
with Gurusinghe et al. [40] who found that morning cortisol
and DHEA-S correlated with ISI in PCOS women. After a
linear regression analysis we showed that LH and insulin
levels may, respectively, positively and negatively predict
cortisol levels.We can thus raise the hypothesis that the lower
levels of insulin in nonobese PCOS women might be also
contributing to the higher adrenocortical production found
in this group compared to obese PCOS women. On the other
hand, the higher levels of insulin in the obese PCOS group
could also be contributing to a lower androgen production of
the adrenal gland.
Also in accordancewith our results, Saxena and Seely [28]
demonstrated that hyperandrogenic women could be divided
into two subgroups: one with insulin resistance (IR), normal,
or minimally elevated LH, and markedly elevated insulin
levels and one with elevated LH levels, no insulin resistance,
and normal insulin concentrations. They found a negative
correlation between LH and insulin, but after eliminating the
effect of BMI, this correlation was no longer significant. We
did not find any correlation between LH and HOMA-IR or
ISI suggesting a minor role of LH in PCOS pathophysiology
in obese women, when compared to nonobese women.
In conclusion, our results indicate an increased adreno-
cortical production, not related to insulin resistance, in
nonobese PCOS women, and associated with a normal HPA
suppression after DEX administration. A neuroendocrine
disturbance characterized by higher levels of LH in nonobese
PCOS womenmight be involved in the increased adrenocor-
tical production in this group. Further studies are needed to
better clarify the role of adrenal gland in the pathophysiology
of PCOS in nonobese women.
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